Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natriuretic peptide receptor 1 (NPR1) is a membrane-bound guanylyl cyclase that serves as the primary receptor for atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). These peptides are potent vasoactive hormones with key roles in cardiovascular and renal homeostasis. Upon ligand binding, NPR1 catalyzes the conversion of GTP to cGMP, leading to vasodilation, natriuresis, and other physiological effects. Dysfunction of NPR1 is associated with heart failure and hypertension, making it a therapeutic target.
Activation of guanylyl cyclase activity upon ANP/BNP binding, leading to increased cGMP production and downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natriuretic Peptide Receptor 1 (NPR1).